We found that signaling of PRL through the LF/IFPRLR raises the risk of B-cell malignancy initiation in SLE-prone mice, increases the survival of pre-malignant B cells in DLBCL-prone mice, and sustains the progression of established human B-cell malignancies. The gene discussed is PRL; the disease is diffuse large B-cell lymphoma.